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ABSTRACT 31 
Background and Aims: to investigate the risk of mortality from infections by comparing the 32 
underlying causes of death versus the multiple causes of death in known diabetic subjects living in 33 
the Veneto Region, Northern Italy.  34 
Methods and Results: 185,341 diabetic subjects aged 30-89 years were identified in the year 2010 35 
and causes of death were assessed from 2010 to 2015. Standardized Mortality Ratios (SMR) with 36 
95% confidence intervals were computed with regional mortality rates as reference. The underlying 37 
causes of death and all the diseases reported in the death certificates were scrutinized. At the end of 38 
the follow-up, 36,382 subjects had deceased. We observed an increased risk of death from 39 
infection-related causes in subjects affected by diabetes with a SMR of 1.83 (95 % CI, 1.71-1.94). 40 
The SMR for death from septicemia was 1.91 (95 % CI, 1.76-2.06) and from pneumonia 1.47 (95 % 41 
CI, 1.36-1.59). The use of the multiple causes of death approach emphasized the contribution of 42 
infectious diseases to mortality.  43 
CONCLUSION: the results of the present study demonstrate an excess mortality from infection-44 
related diseases in patients affected by diabetes and, more interestingly, show a possible 45 
underestimation of the impact of these conditions by routine mortality analyses. 46 
 47 
 48 
 49 
 50 
 51 
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INTRODUCTION 53 
The prevalence of diabetes is steadily rising, and therefore it constitutes a consistent challenge for 54 
health care systems worldwide [1]. In patients affected by diabetes, the main burden in terms of 55 
morbidity and mortality is represented by cardiovascular diseases [2], nevertheless infections are  56 
increasing both in frequency and severity in these patients [3]. Subjects with diabetes have higher 57 
rates of impaired immunity [4,5] and an increased risk for various types of infections when 58 
compared with those without diabetes [6] The impact of infectious diseases is particularly high in 59 
older patients as recently shown [7,8]. The association of diabetes and infections has been reported 60 
in the past and at least two important studies have observed an increased frequency of bacteriuria 61 
and bacteremia in adult women with diabetes versus those without it [9,10]. Besides bacteremia, 62 
diabetes has shown to increase the risk of pneumonia, tuberculosis, urinary tract infections, severe 63 
gram-positive and hospital acquired post-operative infections [3,11]. 64 
It has been reported that 28-day mortality rate is higher among patients affected  by diabetes with 65 
MRSA pneumonia compared to patients without diabetes [12]. Nevertheless, other studies did not 66 
report an increased risk of mortality from community acquired pneumonia in patients with diabetes 67 
[13]. An important Australian study, that involved 1,108,982 individuals with diabetes, reported an 68 
increased risk of mortality from various infections compared to the general population [14]. The 69 
risk of mortality was higher in type 1 patients compared to type 2 patients [14].  70 
The excess risk of death from infectious diseases in patients with diabetes may be multifactorial. An 71 
important role is played by the presence of microangiopathy and renal failure [15]. The other 72 
important factor is hyperglycemia: hyperglycemia on admission has been shown to increase the risk 73 
of pneumonia-related mortality [16].  74 
Considering the important emerging role of infectious diseases in the clinical outcomes of diabetes, 75 
in the present study we analyzed the impact of infections on the risk of mortality in patients with 76 
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diabetes by using both the underlying cause of death (UCOD) and the multiple causes of death 77 
(MCOD) approaches [17]. Through the MCOD approach, it is likely to obtain a more realistic 78 
estimate of mortality burden from infection-related causes [17]. 79 
METHODS 80 
Identification and follow-up of a cohort of diabetic subjects 81 
In the Veneto Region (North-Eastern Italy), hospital care is free of charge, while patients contribute 82 
to out-of-hospital care and drug costs. However, after the certification by a specialist and the 83 
enrollment in an electronic list of subjects with diabetes maintained by Local Health Units, out-of-84 
hospital care related to diabetes (both type 1 and type 2) is free of charge. The electronic regional 85 
archive of subjects with copayment exemption for diabetes is estimated to include about 80% of 86 
subjects identified as diabetics by multiple data sources [18]; therefore it does not include all the 87 
affected residents in the Region because, for example, elderly patients with an income below an 88 
official threshold have access to free outpatient care even if not listed as diabetic subjects. However, 89 
such archive can be the source for the identification of a large cohort of patients; in a previous 90 
survey in the Veneto Region, the positive predictive value of the archive was 98% for the diagnosis 91 
of diabetes in a sample of people aged 18–65 years [19].  92 
For the purpose of this study, we identified in the electronic archive of the Veneto Region a cohort 93 
of diabetic patients aged 30-89 years with copayment exemption for diabetes in January 2010 and 94 
linked them with the archive of causes of deaths occurred in the period 2010-2015. Based on 95 
copayment exemptions, selected comorbidities affecting patients with diabetes were also identified: 96 
cancer, chronic renal failure, heart diseases (congestive heart failure, ischemic and hypertensive 97 
heart diseases), respiratory diseases (chronic respiratory failure, asthma), rheumatoid arthritis, 98 
Parkinson’s disease, and having received an organ transplant. The study was carried out by using 99 
health records previously submitted to a standardized anonymization process assigning to each 100 
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subject a unique code allowing record linkage between electronic archives, without any possibility 101 
of retrieving the identities of patients. Each subject was followed-up from January 1, 2010, either 102 
until death, or 90 years of age, or December 31, 2015, whichever came first.  103 
Analysis of causes of death 104 
A copy of death certificates of all residents in the Veneto Region is centrally transmitted to the 105 
Regional Epidemiological Department for coding of causes of death according to the International 106 
Classification of Diseases, 10th Edition (ICD-10). Since 2008 the electronic regional archive of 107 
mortality includes not only the underlying cause of death, but all diseases mentioned in the death 108 
certificate (MCOD), both in Part I (i.e. conditions involved in the causal chain of events leading to 109 
death), and in Part II (i.e. other significant conditions contributing to death). The selection of the 110 
UCOD is performed by means of the Automated Classification of Medical Entities, which is a 111 
computer program developed by the US National Center for Health Statistics to standardize 112 
assignment of the underlying cause [20]. 113 
To assess mortality in the study cohort, common causes of death routinely reported in mortality 114 
statistics were investigated, including certain infectious diseases (ICD-10 A00-B99), sepsis (A40-115 
A41), and pneumonia (J12-J18). Furthermore, to obtain a broader picture of infections-related 116 
deaths, the following causes were included in a single category: certain infectious diseases (A00-117 
B99, with the exclusion of viral hepatitis B15-B19), respiratory infections (J10-J22, J69, J85-J86), 118 
and urinary infections (N10-N12, N136, N15, N390). Mention of infection diseases was searched 119 
both limited to the UCOD, and among MCOD of the period 2010–2015. 120 
Since all analyses were carried out on routinely collected anonymized health records, the study was 121 
deemed exempt from approval by the Local Ethical Committee. 122 
Statistical analysis 123 
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Standardized Mortality Ratios (SMR) with 95% confidence intervals based on the Poisson 124 
distribution were computed as the ratios between deaths observed in the diabetic cohort, and those 125 
expected according to age- and gender-specific regional mortality rates. SMRs were computed for 126 
both total mortality and the main nosologic categories based on the underlying cause of death. 127 
SMRs were assessed in the whole cohort of diabetic subjects, separately by gender and three classes 128 
of age, and stratified by the presence of comorbidities. 129 
Furthermore, the proportional mortality (share of overall mortality accounted by a specific cause) 130 
for infectious diseases was analyzed by follow-up period (2010-2012 and 2013-2015), both through 131 
the UCOD and the MCOD approaches. 132 
RESULTS 133 
In the present study, 185,341 patients with diabetes were included out of 191,301 identified on 134 
January 2010: 5,960 were excluded for the age limits (< 30 yrs or ≥ 90 yrs). Less than 1 % of 135 
patients were lost during the years of follow-up. At the end of the follow-up 36,382 (24.7 %) 136 
patients had deceased. The main cause of death, in quantitative terms, was represented by 137 
cardiovascular diseases (as shown in table 1), nevertheless the risk of dying from infection-related 138 
causes was quite high, with a SMR of 1.83 (95 % CI, 1.71-1.94). The SMR for death from 139 
septicemia was 1.91 (95 % CI, 1.76-2.06) and that from pneumonia 1.47 (95 % CI, 1.36-1.59), 140 
respectively. It is worth noting that the highest SMRs, with a two-fold increased risk of mortality 141 
with respect to the general population, were observed for sepsis as well as for few already well-142 
known causes of death in diabetic subjects: ischemic heart diseases, liver and pancreatic cancer, and 143 
chronic liver diseases. 144 
Table 2 reports the number of deaths and SMRs for infection-related deaths stratified by sex and 145 
age. In general, SMRs decreased with increasing age in all conditions and the peaks of SMRs were 146 
seen in the group aged 30-64 yrs in both sexes. Females showed higher SMRs, especially in the 147 
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younger age group. The highest risk of dying from infection-related causes was for sepsis, with a 3 148 
and about 5 fold increase in males and females, respectively, aged 30-64 yrs (table 2). The SMRs 149 
for pneumonia in the same age group was 2.18 (95 % CI, 1.16- 3.73) for males and 3.53 (95 % CI, 150 
1.25- 7.68) for females. Of note, figure 2 shows the prevalence of infectious diseases when selected 151 
as the UCOD, or as any mention in the death certificate (MCOD). This figure emphasizes that 152 
infections may largely be underestimated as causes of death. A large difference between UCOD and 153 
MCOD could be observed especially during the second triennium of follow-up for which sepsis was 154 
the main contributor (figure 2). From 2013 to 2015, infectious diseases were selected as the UCOD 155 
in 6.0% of overall deaths, whereas they were mentioned in 20.6% of all death certificates in diabetic 156 
subjects. Table 3 shows the SMRs for common infections and sepsis stratified according to the 157 
comorbidities. The increased risk of death from infections persisted after stratification for the 158 
comorbidities. Some subgroups in the sepsis analysis have few events, but it is still shown that the 159 
trend of SMRs indicates an increase in the risk of mortality. 160 
 161 
DISCUSSION 162 
The main results of this study were: 1) patients with diabetes experienced an excess mortality from 163 
infectious diseases that persisted even when the comorbidities were accounted for by stratified 164 
analysis, 2) excess mortality peaked in younger patients (between 30-64 yrs) and declined 165 
afterwards, 3) SMRs of mortality were higher in females, and 4) the burden of infectious diseases 166 
on mortality became substantial when the MCOD approach was adopted; therefore the use of 167 
UCOD may lead to an underestimation of infectious diseases as cause of death. In the second 168 
triennium of follow-up there was an increase in infection-related mortality and sepsis was the major 169 
contributor to this increase. 170 
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Notably, about 20% of patients with diabetes could not be included in the study, mainly elderly 171 
patients with low economic income. This may represent a selection bias that limits the 172 
generalization of our results. However, this bias may also lead to a further underestimation of the 173 
impact of infectious diseases on total mortality.   174 
During the recent years, infectious diseases have turned out to be a major health problem probably 175 
due to the emergence of multi-resistant bacteria [11,12,13], and the growing number of patients 176 
with altered immune function. Diabetes may compromise the immune system activity at several 177 
levels [3,21].  178 
A retrospective study on 218,805 elderly patients with diabetes showed an high incidence of 179 
community acquired infection (lower respiratory tract and urinary tract infections, sepsis) with 180 
many of them requiring hospitalization [7]. In England, between 2000-2001 and 2010-2011, 181 
hospital admission rates for community-acquired infection more than doubled [8]. Our results 182 
showed an increase in infectious diseases in the interval 2013-2015 compared to 2010-2012. The 183 
increase for sepsis was impressive, maybe related both to a real increase and to more careful 184 
recording of the condition in death certificates [17].  185 
In the younger age group (30-64 yrs), the risk of dying from sepsis or pneumonia was 3-5 and 2-3.5 186 
fold higher in patients with diabetes, with higher relative risks observed in the female gender. 187 
Eventually, the risk of dying from infection-related causes decreased with age. Diabetes is 188 
associated with an increased risk of mortality from different infectious diseases [14] and infections 189 
caused by specific agents such as Pseudomonas aeruginosa [22] or Acinetobacter baumannii [23] .  190 
Our results are in agreement with a recent and large population-based study from Australia [14]. 191 
This Australian study found comparable SMRs for sepsis , while SMRs for pneumonia were higher 192 
in the present study. The Australian study is also important because the authors were able to 193 
distinguish between type 1 and type 2 diabetes, observing higher risks in type 1 diabetes.  194 
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However, instead of recoding the causes of death and conducting a successive analysis as in the 195 
Australian study [14], we analyzed any mention of infections in death certificates. We believe that 196 
this latter approach can better estimate the global burden of infectious diseases on mortality, 197 
contributing also to emphasize the underestimation of the real impact of these diseases on mortality 198 
as shown by our results (figure 2) [17]. 199 
Community-acquired pneumonia, despite modern treatment modalities, still confers a high in-200 
hospital and 30-day risk of mortality [24]. Diabetes is one among all the comorbidities that can 201 
increase the risk of mortality in these patients [24]. Moreover, the 28-day mortality in patients with 202 
diabetes affected by nosocomial pneumonia caused by methicillin-resistant microorganisms was 203 
higher compared to patients without diabetes [12]. The risk of death was sixth-fold higher among 204 
patients with diabetes who were receiving chronic renal dialysis [12].    205 
The relationship among diabetes, immune system function and infections may be mediated by 206 
multiple factors, but at least three of them deserve attention: microangiopathy, renal dysfunction 207 
and other comorbidities, as well as short and long-term hyperglycemia. 208 
Microangiopathy along with hyperglycemia may alter both the permeability and the structure of 209 
glycolipid moiety in the microcirculation [25] increasing the risk of bacteremia [3].  210 
Renal dysfunction seems to be a critical factor of infection-related mortality, as reduced glomerular 211 
filtration rate has been associated to an increased risk (more than double when GFR falls below 30 212 
ml/min/1.73m2) of mortality from infection-related conditions [26] . Even the pre-existence of 213 
chronic kidney disease is associated with an increased short-term risk of mortality following 214 
pneumonia and sepsis [27].  215 
Comorbidities may play an important role in causing the excess mortality from infectious diseases; 216 
a retrospective cohort study found an increased risk for infection-related mortality in adults with 217 
diabetes and reported that the increased risk could be mediated by congestive heart failure [28]. 218 
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However, our study seems to indicate that the risk of mortality from infections was increased even 219 
after stratification by comorbidities (table 3).  220 
Hyperglycemia was shown to impair the chemotaxis of neutrophils, phagocytosis, superoxide 221 
production and killing activity of Staphylococcus aureus [29]. Also short-term episodes of 222 
hyperglycemia may impair IL-6 expression in intermediate monocytes and IL-17A expression, both 223 
of which are responsible for immune dysfunction in critically ill patients [30]. However, the 224 
relationship between glycemia and sepsis is not straightforward. In recent studies it has been shown 225 
that while diabetes mellitus behaves somehow as a protective factor in sepsis patients, hyper- or 226 
hypoglycemia status on admission, and increased blood glucose variability during hospital stay, 227 
were independently associated with an increased risk of mortality [31].   228 
Through all the above mechanisms, patients affected by diabetes are at increased risk of mortality 229 
from infection-related diseases. Our results may have important clinical relevance as they show that 230 
the impact on mortality from infectious diseases, including sepsis, may be largely underestimated if 231 
confined to the UCOD. In fact, the UCOD usually emphasizes the impact of chronic illnesses and 232 
understates the role of infections in the terminal phase leading to death, while MCOD, by analyzing 233 
all conditions reported in the death certificate, may reveal a more realistic picture of the impact of 234 
infections as a cause of mortality [17]. 235 
Our study may have important clinical implications as it suggests that infectious diseases greatly 236 
increase the risk of a worse prognosis in patients affected by diabetes. Even though the absolute risk 237 
based on the UCOD is quite small, it should be emphasized that the real impact of infectious 238 
diseases on mortality may be largely underestimated, as the use of MCOD seems to indicate.   239 
The present study has different strengths: standardized coding of death certificates, inclusion of 240 
deaths in non-hospitalized patients, the large number of subjects, and the use of both UCOD and 241 
MCOD for classifying infection-related causes of death. Limitations of the study are the use of a 242 
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single source of identification of diabetes, the lack of distinction between type 1 and type 2 diabetes 243 
and, finally, the absence of clinical variables such as severity of diabetes, diabetes duration, 244 
glycated hemoglobin and type of hypoglycemic treatment that are difficult to obtain by 245 
administrative databases. 246 
In conclusion, the results of the present study demonstrate an excess mortality from infection-247 
related diseases in patients affected by diabetes and, more interestingly, show a possible 248 
underestimation of the impact of these conditions in causing mortality. 249 
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Table 1. Number of deaths and standardized mortality ratio (SMR) with 95% Confidence Interval 351 
(CI) in a cohort of 185,341 patients with diabetes according to the underlying cause of death. 352 
Reference = expected deaths based on gender- and age-specific mortality rates in the Veneto Region 353 
(Italy), 2010-2015. 354 
 
n 
deaths SMR (CI) 
% all 
deaths 
Certain infectious and parasitic diseases (A00-B99) 1,022 1.83 (1.71-1.94) 2.8% 
Septicemia (A40–A41)  641 1.91 (1.76-2.06) 1.8% 
Neoplasms (C00-D48) 10,870 1.31 (1.28-1.33) 29.9% 
Malignant neoplasms of colon, rectum and anus (C18-C21) 1,048 1.24 (1.17-1.32) 2.9% 
Malignant neoplasm of liver (C22) 1,194 2.26 (2.14-2.40) 3.3% 
Malignant neoplasm of pancreas (C25)  1,159 1.85 (1.74-1.96) 3.2% 
Malignant neoplasms of trachea, bronchus and lung (C33-C34)  2,058 1.17 (1.12-1.22) 5.7% 
Malignant neoplasm of breast (C50)  526 1.26 (1.15-1.37) 1.4% 
Endocrine, nutritional and metabolic diseases (E00-E90) 4,814 5.17 (5.03-5.32) 13.2% 
Diabetes mellitus (E10-E14) 4,518 6.08 (5.90-6.26) 12.4% 
Mental and behavioural disorders (F00-F99) 822 0.98 (0.92-1.05) 2.3% 
Dementia (F00-F03) 785 1.02 (0.95-1.09) 2.2% 
Diseases of the nervous system (G00-G99) 914 0.90 (0.84-0.96) 2.5% 
Diseases of the circulatory system (I00-I99) 12,282 1.53 (1.50-1.55) 33.8% 
Hypertensive diseases (I10-I15) 1,261 1.26 (1.19-1.33) 3.5% 
Ischemic heart diseases (I20-I25) 5,085 1.80 (1.75-1.85) 14.0% 
Other heart diseases (I00-I09, I26-I51) 2,855 1.49 (1.43-1.54) 7.8% 
Cerebrovascular diseases (I60-I69) 2,707 1.41 (1.35-1.46) 7.4% 
Diseases of the respiratory system (J00-J99) 2,088 1.26 (1.21-1.31) 5.7% 
Pneumonia (J12-J18) 665 1.47 (1.36-1.59) 1.8% 
Chronic lower respiratory diseases  (J40–J47)  752 1.13 (1.05-1.21) 2.1% 
Diseases of the digestive system (K00-K93) 1,618 1.72 (1.64-1.80) 4.4% 
Diseases of liver (K70-K76) 799 2.31 (2.15-2.48) 2.2% 
Diseases of the genitourinary system (N00-N95) 550 1.66 (1.52-1.80) 1.5% 
External causes of mortality (V01-Y84) 910 1.30 (1.22-1.39) 2.5% 
All causes 36,382 1.53 (1.51-1.54) 100.0% 
 355 
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 357 
Table 2. Number of deaths and standardized mortality ratio (SMR) with 95% Confidence Interval 358 
(CI) in patients with diabetes, by gender and age class according to the underlying cause of death. 359 
Reference = expected deaths based on gender- and age-specific mortality rates in the Veneto Region 360 
(Italy), 2010-2015. 361 
 Males Females 
 
n SMR (CI) % all deaths n SMR (CI) 
% all 
deaths 
All causes       
30-64 yrs 2,209 2.18 (2.09-2.27) - 729 2.47 (2.29-2.65) - 
65-74 yrs 5,644 1.72 (1.67-1.76) - 2,349 1.95 (1.88-2.04) - 
75-89 yrs 13,159 1.35 (1.33-1.38) - 12,292 1.48 (1.46-1.51) - 
Sepsis       
30-64 yrs 30 3.00 (2.02-4.28) 1.4% 16 4.98 (2.84-8.08) 2.2% 
65-74 yrs 90 2.44 (1.96-3.00) 1.6% 52 3.67 (2.74-4.81) 2.2% 
75-89 yrs 233 1.63 (1.43-1.85) 1.8% 220 1.72 (1.50-1.96) 1.8% 
Pneumonia       
30-64 yrs 13 2.18 (1.16-3.73) 0.6% 6 3.53 (1.29-7.68) 0.8% 
65-74 yrs 57 1.91 (1.45-2.47) 1.0% 33 3.21 (2.21-4.51) 1.4% 
75-89 yrs 306 1.38 (1.23-1.55) 2.3% 250 1.37 (1.20-1.55) 2.0% 
Common infections*       
30-64 yrs 70 1.96 (1.53-2.48) 3.2% 38 4.02 (2.84-5.51) 5.2% 
65-74 yrs 205 1.79 (1.55-2.05) 3.6% 113 2.42 (1.99-2.91) 4.8% 
75-89 yrs 753 1.33 (1.23-1.43) 5.7% 692 1.30 (1.20-1.40) 5.6% 
*Common infections: some infectious diseases A00-B99 - with the exclusion viral hepatitis B15-362 
B19; respiratory infections J10-J22, J69, J85-J86; urinary infections N10-N12, N136, N15, N390 363 
 364 
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Table 3. Number of deaths and standardized mortality ratio (SMR) with 95% Confidence Interval 373 
(CI) in patients with diabetes, by gender and comorbidities according to the underlying cause of 374 
death. Reference = expected deaths based on gender- and age-specific mortality rates in the Veneto 375 
Region (Italy), 2010-2015. 376 
 Males Females 
 N SMR (CI) n SMR (CI) 
Common infections*     
No comorbidities 540 1.25 (1.14-1.36) 478 1.22 (1.11-1.33) 
Any comorbidity 488 1.71 (1.57-1.87) 365 1.85 (1.67-2.05) 
Cancer 123 1.35 (1.12-1.61) 85 1.50 (1.19-1.85) 
Chronic renal failure 47 4.09 (3.00-5.44) 28 5.17 (3.44-7.48) 
Heart diseases 344 1.71 (1.53-1.90) 260 1.88 (1.66-2.12) 
Respiratory diseases 29 1.96 (1.31-2.81) 21 2.25 (1.39-3.44) 
Rheumatoid arthritis 14 4.39 (2.40-7.36) 15 2.36 (1.32-3.90) 
Parkinson’s disease 13 2.98 (1.58-5.09) 9 2.24 (1.02-4.26) 
Transplant 8 9.27 (3.99-18.3) 5 22.8 (7.35-53.2) 
Sepsis     
No comorbidities 188 1.63 (1.41-1.88) 165 1.69 (1.45-1.97) 
Any comorbidity 165 2.21 (1.88-2.57) 123 2.55 (1.12-3.04) 
Cancer 42 1.76 (1.27-2.37) 23 1.62 (1.03-2.43) 
Chronic renal failure 18 5.87 (3.48-9.28) 15 11.3 (6.30-18.6) 
Heart diseases 119 2.25 (1.87-2.70) 90 2.69 (2.16-3.31) 
Respiratory diseases 4 1.04 (0.28-2.66) 6 2.55 (0.93-5.55) 
Rheumatoid arthritis 5 5.87 (1.89-13.7) 3 1.88 (0.38-5.48) 
Parkinson’s disease 3 2.64 (0.53-7.72) 5 5.23 (1.68-12.2) 
Transplant 3 11.5 (2.30-33.5) 2 30.0 (3.37-108) 
*Common infections: some infectious diseases A00-B99 - with the exclusion viral hepatitis B15-377 
B19; respiratory infections J10-J22, J69, J85-J86; urinary infections N10-N12, N136, N15, N390 378 
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FIGURE LEGENDS 383 
Figure 1. Contribution of infectious diseases selected as the underlying cause of death (UCOD), or 384 
contributing causes of death, among 36,382 decedents from a cohort of 185,341 patients with 385 
diabetes. The results are stratified by the two triennial periods of the follow-up. 386 
 387 
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Highlights 
 
Infections are growing as a major problem in diabetes. 
The risk of dying from infections in diabetes is quite high. 
Septicemia and pneumonia are major threatens. 
Multiple causes of death approach may give a more realistic estimate of mortality. 
